Biocon Ltd. — Investor Relations & Filings
Biocon Ltd. is a global biopharmaceutical company focused on developing innovative therapies for chronic conditions such as diabetes, oncology, and autoimmune diseases. The company specializes in the research, development, and manufacture of high-quality biosimilars, generic active pharmaceutical ingredients (APIs), and novel biologics. Its portfolio includes recombinant human insulin, insulin analogs, and monoclonal antibodies. Biocon leverages an integrated business model encompassing advanced research and development, large-scale manufacturing, and global commercialization. By prioritizing affordable innovation, the company aims to enhance access to life-saving treatments across international markets, including the United States, Europe, and emerging economies. Its technical expertise in microbial fermentation and complex protein engineering supports a robust pipeline of complex therapeutics designed to address unmet medical needs.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Company Statement | 2026-05-11 | English | |
| Updates | 2026-05-11 | English | |
| Copy of Newspaper Publication | 2026-05-09 | English | |
| Copy of Newspaper Publication | 2026-05-09 | English | |
| Newspaper Advertisement-Postal Ballot Notice | 2026-05-09 | English | |
| Newspaper Advertisement - Financial Results | 2026-05-09 | English |
Browse filings by year
17 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 44849027 | Company Statement | 2026-05-11 | English | ||
| 44849096 | Updates | 2026-05-11 | English | ||
| 44648096 | Copy of Newspaper Publication | 2026-05-09 | English | ||
| 44648098 | Copy of Newspaper Publication | 2026-05-09 | English | ||
| 44723223 | Newspaper Advertisement-Postal Ballot Notice | 2026-05-09 | English | ||
| 44723224 | Newspaper Advertisement - Financial Results | 2026-05-09 | English | ||
| 44723225 | Postal Ballot Notice | 2026-05-08 | English | ||
| 44424232 | Shareholders meeting | 2026-05-08 | English | ||
| 44315704 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-05-08 | English | ||
| 44723226 | Audio and video recording of Q4 2026 | 2026-05-08 | English | ||
| 43955963 | Investor Presentation | 2026-05-08 | English | ||
| 44723230 | Investor Presentation | 2026-05-08 | English | ||
| 43390572 | Monitoring Agency Report | 2026-05-07 | English | ||
| 44723231 | Outcome of Board Meeting_Monitoring Agency Report | 2026-05-07 | English | ||
| 43348518 | Record Date | 2026-05-07 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Century Therapeutics, Inc.
Develops iPSC-derived allogeneic cell therapies for cancer …
|
IPSC | US | Manufacturing |
|
Cereno Scientific AB
Clinical-stage biotech developing drugs for rare cardiovasc…
|
CRNO | SE | Manufacturing |
|
CERO THERAPEUTICS HOLDINGS, INC.
Immunotherapy company developing engineered T cell therapeu…
|
CERO | US | Manufacturing |
|
CERUS CORP
Develops pathogen inactivation technology to reduce transfu…
|
CERS | US | Manufacturing |
|
Cessatech A/S
A biotech company developing medicines for children's acute…
|
CESSA | DK | Manufacturing |
|
CF PharmTech
Develops and manufactures inhalation drugs and delivery sys…
|
2652 | CN | Manufacturing |
|
CF PharmTech, Inc.
Specialty pharmaceutical company developing complex inhalat…
|
2652 | HK | Manufacturing |
|
CG Invites Co., Ltd.
A biopharmaceutical company specializing in digital genomic…
|
083790 | KR | Manufacturing |
|
CG Oncology, Inc.
Develops bladder-sparing oncolytic immunotherapies for urol…
|
CGON | US | Manufacturing |
|
Changchun Bcht Biotechnology Co.
Biopharmaceutical firm focused on the R&D and production of…
|
688276 | CN | Manufacturing |
Biocon Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/61176/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=61176 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=61176 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=61176 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 61176}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Biocon Ltd. (id: 61176)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.